

DYNAVAX TECHNOLOGIES CORP  
Form 8-K  
July 22, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 8-K**

**Current Report**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): July 20, 2011**

**Dynavax Technologies Corporation**

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware  
(State or other jurisdiction)

33-0728374  
(IRS Employer)

Edgar Filing: DYNAVAX TECHNOLOGIES CORP - Form 8-K

of incorporation)

Identification No.)

**2929 Seventh Street, Suite 100**

**Berkeley, CA 94710-2753**

(Address of principal executive offices, including zip code)

**(510) 848-5100**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On July 20, 2011 at 9:00 a.m. Eastern Daylight Time, Dynavax Technologies Corporation ( Dynavax ) hosted a conference call and live webcast to discuss its HEPLISAV Phase 3 top-line data along with its financial results for the second quarter ended June 30, 2011. A copy of the conference call transcript is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibit

<b>Exhibit No.</b>	<b>Description</b>
99.1	Conference Call Transcript dated July 20, 2011.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DYNAVAX TECHNOLOGIES CORPORATION**

Date: July 22, 2011

By: /s/ Michael S. Ostrach  
Michael S. Ostrach

Vice President

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Conference Call Transcript dated July 20, 2011.